(lp0
S"Here's Why ImmunoGen, Inc. Skyrocketed 45% in February Motley Fool - Mar 9, 2017 Shares of ImmunoGen , a small-cap biopharmaceutical company that utilizes its proprietary antibody-drug conjugate  technology to fight various forms of cancer, skyrocketed 45% during February, according to data from S&amp;P Global&nbsp;...The 4.5% Stake of ImmunoGen, Inc.  Owned by Primecap Management Company - DailyQuint"
p1
aS"Why ImmunoGen, Inc. Skyrocketed Higher Today Motley Fool - Feb 27, 2017 It's also possible investors are buying ahead of the Society of Gynecologic Oncology's Annual Meeting of Women's Cancer next month where ImmunoGen is scheduled to present additional phase 1 data from a subset of patients getting its cancer medication&nbsp;...ImmunoGen Inc  Has A Wave Of Catalysts About To Hit Press - Insider FinancialImmunoGen, Inc.  Update On Trial of Mirvetuximab Soravtansine - Journal Transcript"
p2
aS"ImmunoGen's Mirva May Have Activity In FR High Ovarian Cancer Seeking Alpha - 14 hours ago Immunogen  is a nanocap clinical stage biopharma developing Mirventuximab soravtansine, an antibody-drug conjugate  with a monoclonal antibody  that binds to FRalpha-positive tumor cells thereby delivering&nbsp;..."
p3
aS"3 Charts That Show the Potential Risks and Rewards for Immunogen, Inc. Stock Motley Fool - Mar 4, 2017 After 36 years of being in business, Immunogen  has yet to make a profit. Unfortunately, the biotech still isn't close to reaching break-even status."
p4
aS'ImmunoGen  Up 47.2% Since Earnings Report: Can It Continue? Yahoo Finance - 21 hours ago A month has gone by since the last earnings report for ImmunoGen, Inc. IMGN. Shares have added about 47.2% in that time frame, outperforming the market.'
p5
aS'Immunogen Inc.  PT Lowered to $1.30 at Morgan Stanley StreetInsider.com - Mar 1, 2017 Morgan Stanley lowered its price target on Immunogen Inc.  to $1.30  while maintaining a Underweight rating.'
p6
aS'Do Analysts See Any Promise for These Stocks: ImmunoGen, Inc. (NASDAQ:IMGN ... Rives Journal - 14 hours ago ImmunoGen, Inc.  shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm.'
p7
aS'Chart Watch: Checking on Shares of ImmunoGen Inc  Davidson Register - 12 hours ago Technical traders have a large inventory of technical indicators they may use when doing technical stock analysis. After a recent look, the 14-day ATR for ImmunoGen Inc  is resting at 0.26. First developed by J. Welles Wilder, the ATR may help ...'
p8
aS'Quick Look At Sell-Side Ratings on ImmunoGen, Inc.  Packaging ... Davidson Register - 8 hours ago Sell-side analysts are offering a consensus Buy rating on shares of ImmunoGen, Inc. . Using the following ratings scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell and 5.0 Strong Sell, analysts have an average recommendation of 2.40.Watching the Next Move of ImmunoGen, Inc.  - The Oracle ExaminerStock Price of ImmunoGen, Inc.  Decreases -4.02% - Highland Mirror'
p9
aS'ImmunoGen Inc.  Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 ImmunoGen Inc.  traded on unusually high volume on Mar. 10, as the stock gained 1.91% to close at $3.73. On the day, ImmunoGen Inc. saw 4.78 million shares trade hands on 14,569 trades. Considering that the stock averages only a daily volume of&nbsp;...Stock Showing Surging Activity: ImmunoGen, Inc.  - HugoPressBrokers Issue New Targets On ImmunoGen, Inc.  - Fiscal Standard'
p10
a.